News FAMHP

There are 68 result(s) found based on your search criteria

11-20 from 68 result(s)

Ranitidine: recall of medicines

A nitrosamine impurity (NDMA, N-nitrosodimethylamine) has been detected in medicines based on ranitidine. The European Medicines Agency (EMA) has started a review. As a precautionary measure, the companies involved are recalling the medicine or placing the medicines in quarantine.

Information on the Falsified Medicines Directive available in the online medicines database

The Falsified Medicines Directive (FMD), sets forth a number of measures to prevent the introduction of falsified medicines on the market. Thus, all packages of medicines that fall under this regulation must have a unique code and an anti-tampering device (ATD). On packages that do not fall under this obligation, marketing authorization holders can voluntarily attach an ATD. This information is now available in the online medicines database.

EU and US reach milestone in mutual recognition of medicines manufacturers inspections

The U.S. Food and Drug Administration (U.S. FDA) has recognized all 28 EU member states. This means that starting 11 July 2019, the United States (US) and the European Union (EU) have fully implemented the mutual recognition agreement (MRA) for inspections of manufacturing sites for certain human medicines in their respective territories.

PRAC May 2019 – Start of referral: Xeljanz (tofacitinib)

During its meeting of May 2019, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has started a referral for Xeljanz (tofacitinib). PRAC has issued restrictions in use of Xeljanz while EMA reviews risk of blood clots in lungs.

Safety signal following early results from an ongoing study with Xeljanz (tofacitinib) in patients with rheumatoid arthritis – Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis

EMA is advising healthcare professionals and patients not to exceed the recommended dose of Xeljanz (tofacitinib) when treating rheumatoid arthritis. The advice follows early results from an ongoing study (study A3921133) in patients with rheumatoid arthritis which showed an increased risk of blood clots in the lungs and death when the normal dose of 5 mg twice daily was doubled.

European medicines authorities take further action in ongoing review of sartans

European medicines authorities have placed the Chinese company Zheijiang Huahai under increased supervision and the Indian company Aurobindo Pharma is no longer allowed to supply irbesartan to EU member states.

Update on review of certain recalled lots of valsartan medicines

The European Medicines Agency (EMA) is conducting a review of the possible health effects in patients who may have taken certain lots of valsartan medicines containing an impurity called NDMA. This impurity was found in the active substance manufactured by Zhejiang Huahai Pharmaceuticals.

VIG-NEWS: January 2015 Edition

The new edition of the electronic newsletter "VIG-NEWS" of the federal agency for medicines and health products (famhp) is now available. The VIG-NEWS is a selection of recent news concerning pharmacovigilance from different sources.

Antitussives and decongestants: judgement of the Council of State

In its judgments of 4th July 2013 the Council of State cancelled the decisions of 21st December 2011 of famhp leading to the modification of the marketing authorizations (MA) of antitussives and decongestants held by Medgenix, Qualiphar and Novartis.

Intravenously administered iron-containing medicines: new recommendations

The Committee for Medicinal Products for Human Use of the European Medicines Agency has reassessed the benefit / risk balance of injectable iron-containing medicines for intravenous administration. This Committee believes that their benefits outweigh their risks provided that adequate measures are taken to minimize the occurrence of allergic reactions.

11-20 from 68 result(s)